Literature DB >> 19801990

Development of universal antidotes to control aptamer activity.

Sabah Oney1, Ruby T S Lam, Kristin M Bompiani, Charlene M Blake, George Quick, Jeremy D Heidel, Joanna Yi-Ching Liu, Brendan C Mack, Mark E Davis, Kam W Leong, Bruce A Sullenger.   

Abstract

With an ever increasing number of people taking numerous medications, the need to safely administer drugs and limit unintended side effects has never been greater. Antidote control remains the most direct means to counteract acute side effects of drugs, but, unfortunately, it has been challenging and cost prohibitive to generate antidotes for most therapeutic agents. Here we describe the development of a set of antidote molecules that are capable of counteracting the effects of an entire class of therapeutic agents based upon aptamers. These universal antidotes exploit the fact that, when systemically administered, aptamers are the only free extracellular oligonucleotides found in circulation. We show that protein- and polymer-based molecules that capture oligonucleotides can reverse the activity of several aptamers in vitro and counteract aptamer activity in vivo. The availability of universal antidotes to control the activity of any aptamer suggests that aptamers may be a particularly safe class of therapeutics.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801990      PMCID: PMC3008622          DOI: 10.1038/nm.1990

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  36 in total

Review 1.  The heparin-protamine interaction. A review.

Authors:  J A Carr; N Silverman
Journal:  J Cardiovasc Surg (Torino)       Date:  1999-10       Impact factor: 1.888

2.  Blocking the initiation of coagulation by RNA aptamers to factor VIIa.

Authors:  C P Rusconi; A Yeh; H K Lyerly; J H Lawson; B A Sullenger
Journal:  Thromb Haemost       Date:  2000-11       Impact factor: 5.249

3.  Generation of species cross-reactive aptamers using "toggle" SELEX.

Authors:  R White; C Rusconi; E Scardino; A Wolberg; J Lawson; M Hoffman; B Sullenger
Journal:  Mol Ther       Date:  2001-12       Impact factor: 11.454

4.  Mfold web server for nucleic acid folding and hybridization prediction.

Authors:  Michael Zuker
Journal:  Nucleic Acids Res       Date:  2003-07-01       Impact factor: 16.971

5.  New class of polymers for the delivery of macromolecular therapeutics.

Authors:  H Gonzalez; S J Hwang; M E Davis
Journal:  Bioconjug Chem       Date:  1999 Nov-Dec       Impact factor: 4.774

6.  Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.

Authors: 
Journal:  Retina       Date:  2002-04       Impact factor: 4.256

7.  Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results.

Authors: 
Journal:  Ophthalmology       Date:  2003-05       Impact factor: 12.079

8.  Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.

Authors:  Mark E Kleinman; Kiyoshi Yamada; Atsunobu Takeda; Vasu Chandrasekaran; Miho Nozaki; Judit Z Baffi; Romulo J C Albuquerque; Satoshi Yamasaki; Masahiro Itaya; Yuzhen Pan; Binoy Appukuttan; Daniel Gibbs; Zhenglin Yang; Katalin Karikó; Balamurali K Ambati; Traci A Wilgus; Luisa A DiPietro; Eiji Sakurai; Kang Zhang; Justine R Smith; Ethan W Taylor; Jayakrishna Ambati
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

Review 9.  Self-assembling nucleic acid delivery vehicles via linear, water-soluble, cyclodextrin-containing polymers.

Authors:  M E Davis; S H Pun; N C Bellocq; T M Reineke; S R Popielarski; S Mishra; J D Heidel
Journal:  Curr Med Chem       Date:  2004-01       Impact factor: 4.530

10.  RNA aptamers as reversible antagonists of coagulation factor IXa.

Authors:  Christopher P Rusconi; Elizabeth Scardino; Juliana Layzer; George A Pitoc; Thomas L Ortel; Dougald Monroe; Bruce A Sullenger
Journal:  Nature       Date:  2002-09-05       Impact factor: 49.962

View more
  46 in total

1.  Polycation-siRNA nanoparticles can disassemble at the kidney glomerular basement membrane.

Authors:  Jonathan E Zuckerman; Chung Hang J Choi; Han Han; Mark E Davis
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-06       Impact factor: 11.205

Review 2.  Translating nucleic acid aptamers to antithrombotic drugs in cardiovascular medicine.

Authors:  Thomas J Povsic; Bruce A Sullenger; Steven L Zelenkofske; Christopher P Rusconi; Richard C Becker
Journal:  J Cardiovasc Transl Res       Date:  2010-11-16       Impact factor: 4.132

3.  Targeting Two Coagulation Cascade Proteases with a Bivalent Aptamer Yields a Potent and Antidote-Controllable Anticoagulant.

Authors:  Erin E Soule; Kristin M Bompiani; Rebecca S Woodruff; Bruce A Sullenger
Journal:  Nucleic Acid Ther       Date:  2015-11-19       Impact factor: 5.486

Review 4.  Modulation of the Coagulation Cascade Using Aptamers.

Authors:  Rebecca S Woodruff; Bruce A Sullenger
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-08-27       Impact factor: 8.311

5.  Biologics: The quest for a universal antidote.

Authors:  Monica Hoyos Flight
Journal:  Nat Rev Drug Discov       Date:  2009-12       Impact factor: 84.694

6.  Probing the coagulation pathway with aptamers identifies combinations that synergistically inhibit blood clot formation.

Authors:  Kristin M Bompiani; Jens L Lohrmann; George A Pitoc; James W Frederiksen; George B Mackensen; Bruce A Sullenger
Journal:  Chem Biol       Date:  2014-07-24

7.  Nucleic acid-binding polymers as anti-inflammatory agents.

Authors:  Jaewoo Lee; Jang Wook Sohn; Ying Zhang; Kam W Leong; David Pisetsky; Bruce A Sullenger
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-15       Impact factor: 11.205

8.  Aptamer photoregulation in vivo.

Authors:  Lele Li; Rong Tong; Hunghao Chu; Weiping Wang; Robert Langer; Daniel S Kohane
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-17       Impact factor: 11.205

Review 9.  Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2.

Authors:  Federico Carbone; Priscila Camillo Teixeira; Vincent Braunersreuther; François Mach; Nicolas Vuilleumier; Fabrizio Montecucco
Journal:  Antioxid Redox Signal       Date:  2014-04-22       Impact factor: 8.401

10.  Dependence of aptamer activity on opposed terminal extensions: improvement of light-regulation efficiency.

Authors:  Maximilian C R Buff; Florian Schäfer; Bernhard Wulffen; Jens Müller; Bernd Pötzsch; Alexander Heckel; Günter Mayer
Journal:  Nucleic Acids Res       Date:  2009-12-08       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.